中药小复方“松友饮”通过调节分化抑制因子Id而抑制化疗后肝癌干细胞特性的改变

对现有常用治疗方法耐药的、具有干细胞特性（stemness）的肝癌细胞是导致治疗的失败主要根源，针对具有干细胞特性的肝癌细胞是具有理想前景的治疗策略。本课题前期的研究发现，阻断肝癌血供或化疗可引起残余肝癌细胞转移特性的提高，诱发肝癌细胞发生上皮-间质转化（EMT）。而应用中药小复方"松友饮"可抑制化疗后肝癌细胞发生EMT，并抑制肝癌细胞的干细胞特性，如干细胞标志CD90/EPCAM阳性细胞减少，并发现其抑制肝癌干细胞特性同时抑制分化抑制因子Ids的表达有关。本课题拟在前期研究的基础上，通过体外化疗诱导模型和体内化疗诱导模型，明确化疗诱导后Ids信号途径调控肝癌干细胞特性的作用机理；并进一步研究"松友饮"对Ids信号途径调节作用，明确"松友饮"抑制化疗诱导的肝癌干细胞特性改变的机制。为中药小复方"松友饮"以肝癌干细胞为靶点，联合目前常用肝癌治疗方法，提高肝癌治疗效果提供理论支持。

The effect of current option to treat hepatocellular carcinoma (HCC) is limited due to fail to eliminate resistant tumor cell with tumor stem cell characteristics (stemness). Therefore, targeting to tumor stem cell is a reasonable option. Previous studies showed after blockage of tumor blood supply or chemotherapy the residual tumor cell acquired more aggressive behavior such increasing metastasis potential and epithelial-mesenchymal transition (EMT). We also fund Chinese medicine "song you yin" could reverse the EMT of residual tumor in HCC after treatment with chemotherapeutic agent oxaliplatin. Further results showed that "song you yin" eliminate the CD90+ /EPCAM+ subtype HCC cells and this effect had close relation to inhibiting over expression of Inhibitor of Differentiation/DNA Binding (Id). Based on the previous results we will clarify the role of Ids signal pathway in chemotherapy induced HCC stemness changes and reveal the mechanisms underlying the "song you yin" inhibition of stemness of HCC after chemotherapeutic agents treatment. We hope this research will provide the theoretic support for Chinese medicine targeting to HCC stem cell and taking the important role in the integrated therapy for HCC.